{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.6","value":"62.6"},{"groupId":"OG001","spread":"29.5","value":"62.3"},{"groupId":"OG002","spread":"9.7","value":"68.7"},{"groupId":"OG003","spread":"15.9","value":"75.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Baseline (pre-treatment)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.8","value":"57.5"},{"groupId":"OG001","spread":"16.4","value":"72.9"},{"groupId":"OG002","spread":"2.1","value":"68.7"},{"groupId":"OG003","spread":"12.5","value":"76.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Pre-Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.0","value":"65.2"},{"groupId":"OG001","spread":"9.1","value":"73.5"},{"groupId":"OG002","spread":"5.5","value":"68.3"},{"groupId":"OG003","spread":"14.1","value":"71.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Post-Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2","value":"74.1"},{"groupId":"OG002","spread":"12.2","value":"80.3"},{"groupId":"OG003","spread":"29.7","value":"68.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Six Months Post-Chemo"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"68.9"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"53.3"},{"groupId":"OG002","spread":"22.6","value":"73.0"},{"groupId":"OG003","spread":"31.4","value":"49.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"End of Bevacizumab (BEV)"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"54.0"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"53.0"},{"groupId":"OG002","spread":"7.8","value":"87.5"},{"groupId":"OG003","spread":"26.2","value":"70.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Six Months after BEV"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"71.7"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"56.0"},{"groupId":"OG002","spread":"15.2","value":"76.3"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG003","spread":"NA","value":"77.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"2 Years after BEV"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"76.4"},{"groupId":"OG002","spread":"17.7","value":"80.5"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG003","spread":"NA","value":"76.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"3 Years after BEV"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"24.7","value":"71.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"4 Years after BEV"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"17.0","value":"78.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"5 Years after BEV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Patient reported quality of life was measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). Each item in the FACT-O TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. The FACT-O TOI score ranges 0-100 with a large score suggests better QOL","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Carboplatin and Paclitaxel)"},{"description":"Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Oxaliplatin and Capecitabine)"},{"description":"Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Carboplatin, Paclitaxel, Bevacizumab)"},{"description":"Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.\n\nBevacizumab: Given IV\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG003","title":"Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)"}],"paramType":"MEAN","populationDescription":"All Randomized Patients with at least one post-baseline QOL assessment reported were averaged. Data were not collected at certain time points for certain arms.","reportingStatus":"POSTED","timeFrame":"baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5","title":"Patient Reported Quality of Life","type":"SECONDARY","unitOfMeasure":"units on a scale"}